

## We Claim:

- 1 1. (Original) A clear ibuprofen composition comprising:
  - 2 a. from about 15% to about 40% w/w of ibuprofen,
  - 3 b. from about 30% to about 70% w/w of polyethylene glycol,
  - 4 c. from about 1% to about 10% w/w of a metal carbonate, and
  - 5 d. from about 1% to about 10% w/w of water.
- 1 2. (Cancelled)
- 1 3. (Original) The composition according to claim 1 wherein the polyethylene glycol  
2 has an average molecular weight of about 300 to about 1000.
- 1 4. (Cancelled)
- 1 5. (Original) The composition according to claim 1 wherein the metal carbonate  
2 comprises one or more of sodium bicarbonate, calcium carbonate, potassium  
3 bicarbonate, sodium carbonate, potassium carbonate, magnesium carbonate,  
4 magnesium bicarbonate, or mixtures thereof.
- 1 6. (Cancelled)
- 1 7. (Original) The composition according to claim 1 further comprising one or more  
2 active ingredients, wherein the active ingredients comprise one or more of  
3 glucosamine, pseudoephedrine, codeine, paracetamol, econazole, hydrocodone,  
4 COX-2 inhibitors, alprazolam, dextromethorphan, chlorpheniramine, and  
5 pharmaceutically acceptable salts thereof.
- 1 8. (Original) The composition according to claim 7 wherein the active ingredient  
2 comprises pseudoephedrine and pharmaceutically acceptable salts thereof.
- 1 9. (Original) The composition according to claim 1 wherein the composition is filled  
2 into soft gelatin capsules.
- 1 10. (Original) A process of preparing a clear ibuprofen composition, the process  
2 comprising the steps of:
  - 3 a. dissolving one or more metal carbonates in water to form a solution,

- 4           b. adding ibuprofen and the solution of step (a) to polyethylene glycol with  
5           optional heating, and
- 6           c. stirring to obtain a clear solution.
- 1   11.   (Cancelled)
- 1   12.   (Original) The process according to claim 10 wherein the polyethylene glycol has  
2           an average molecular weight of about 300 to about 1000.
- 1   13.   (Cancelled)
- 1   14.   (Original) The process according to claim 10 wherein the metal carbonate  
2           comprises one or more of sodium bicarbonate, calcium carbonate, potassium  
3           bicarbonate, sodium carbonate, potassium carbonate, magnesium carbonate,  
4           magnesium bicarbonate, or mixtures thereof.
- 1   15.   (Cancelled)
- 1   16.   (Original) The process according to claim 10 further comprising one or more  
2           active ingredients, wherein the active ingredients comprise one or more of  
3           glucosamine, pseudoephedrine, codeine, paracetamol, econazole, hydrocodone,  
4           COX-2 inhibitors, alprazolam, dextromethorphan, chlorpheniramine, and  
5           pharmaceutically acceptable salts thereof.
- 1   17.   (Original) The process according to claim 16 wherein the active ingredient  
2           comprises pseudoephedrine and pharmaceutically acceptable salts thereof.
- 1   18.   (Original) The process according to claim 10 further comprising filling the solution  
2           into a soft gelatin capsules.
- 1   19.   (Original) A soft gelatin capsule of ibuprofen, filled with a clear solution  
2           comprising:
- 3           a. from about 15% to about 40% w/w of ibuprofen,  
4           b. from about 30% to about 70% w/w of polyethylene glycol,  
5           c. from about 1% to about 10% w/w of a metal carbonate, and  
6           d. from about 1% to about 10% w/w of water.
- 1   20.   (Original) The soft gelatin capsule of claim 19 wherein gelatin mass of the capsule  
2           comprises gelatin, water, plasticizers, coloring agents and preservatives.

- 1 21. (Previously Amended) The soft gelatin capsule of claim 20 wherein the plasticizers  
2 comprises sorbitol special solution and andrisorb.
- 1 22. (Original) The soft gelatin capsule of claim 20 wherein the ratio of gelatin to water  
2 varies from 1:0.75 to 1:0.92 and the ratio of gelatin to plasticizer varies from  
3 1:0.35 to 1:0.48.
- 1 23. (Original) The soft gelatin capsule according to claim 19 further comprising one or  
2 more active ingredients, selected from glucosamine, pseudoephedrine, codeine,  
3 paracetamol, econazole, hydrocodone, COX-2 inhibitors, alprazolam,  
4 dextromethorphan, chlorpheniramine, and pharmaceutically acceptable salts  
5 thereof.
- 1 24. (Original) The soft gelatin capsule according to claim 23 wherein the one or more  
2 active ingredient is pseudoephedrine and pharmaceutically acceptable salts thereof.
- 1 25. (Cancelled)
- 1 26. (Cancelled)
- 1 27. (Original) A clear ibuprofen-pseudoephedrine composition comprising:  
1 a. from about 15% to about 40% w/w of ibuprofen,  
2 b. from about 3% to about 6% w/w of pseudoephedrine or a pharmaceutically  
3 acceptable salt thereof,  
4 c. from about 30% to about 70% w/w of polyethylene glycol,  
5 d. from about 1% to about 10% w/w of a metal carbonate, and  
6 e. from about 1% to about 10% w/w of water.
- 1 28. (Cancelled)
- 1 29. (Original) The composition according to claim 27 wherein the polyethylene glycol  
2 has an average molecular weight of about 300 to about 1000.
- 1 30. (Cancelled)
- 1 31. (Original) The composition according to claim 27 wherein the metal carbonate  
2 comprises one or more of sodium bicarbonate, calcium carbonate, potassium  
3 bicarbonate, sodium carbonate, potassium carbonate, magnesium carbonate,  
4 magnesium bicarbonate, or mixtures thereof.

- 1 32. (Cancelled)
- 1 33. (Original) The composition according to claim 27 further comprising one or more  
2 active ingredients, wherein the active ingredient comprise one or more of  
3 glucosamine, codeine, paracetamol, econazole, hydrocodone, COX-2 inhibitors,  
4 alprazolam, dextromethorphan, chlorpheniramine, and pharmaceutically acceptable  
5 salts thereof.
- 1 34. (Original) The composition according to claim 27 wherein the composition is filled  
2 into soft gelatin capsules.
- 1 35. (Original) A process of preparing a clear ibuprofen-pseudoephedrine composition  
2 comprising the steps of:
- 3 a. dissolving one or more metal carbonates in water to form a solution,  
4 a. adding ibuprofen and the solution of step (a) to polyethylene glycol with  
5 optional heating,  
6 b. stirring to obtain a clear solution, and  
7 c. adding pseudoephedrine or a pharmaceutically acceptable salt thereof, and  
8 stirring to obtain a clear solution.
- 1 36. (Original) The process according to claim 35 further comprising filling the solution  
2 of step (d) into a soft gelatin capsule.
- 1 37. (Cancelled)
- 1 38. (Cancelled)
- 1 39. (Original) A clear ibuprofen composition comprising:  
2 a. from about 15% to about 40% w/w of ibuprofen,  
3 b. from about 30% to about 65% w/w of polyethylene glycol,  
4 c. from about 1% to about 10% w/w of a metal carbonate,  
5 d. from about 1% to about 15% w/w of a surfactant, and  
6 e. from about 1% to about 10% w/w of water.
- 1 40. (Cancelled)

- 1 41. (Original) The composition according to claim 39 wherein the polyethylene glycol  
2 has an average molecular weight of about 300 to about 1000.
- 1 42. (Cancelled)
- 1 43. (Original) The composition according to claim 39 wherein the metal carbonate  
2 comprises one or more of sodium bicarbonate, calcium carbonate, potassium  
3 bicarbonate, sodium carbonate, potassium carbonate, magnesium carbonate,  
4 magnesium bicarbonate, or mixtures thereof.
- 1 44. (Original) The composition according to claim 39 wherein the surfactant is a non-  
2 ionic hydrophilic surfactant.
- 1 45. (Original) The composition according to claim 44 wherein the non-ionic  
2 hydrophilic surfactant comprises one or more of polyoxyethylene alkylethers,  
3 polyethylene glycol fatty acids esters, polyethylene glycol glycerol fatty acid  
4 esters, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene-  
5 polyoxypropylene block copolymers, polyglyceryl fatty acid esters,  
6 polyoxyethylene glycerides, polyoxyethylene vegetable oils, and polyoxyethylene  
7 hydrogenated vegetable oils.
- 1 46. (Original) The composition according to claim 39 further comprising one or more  
2 active ingredients, wherein the active ingredients comprise one or more of  
3 glucosamine, pseudoephedrine, codeine, paracetamol, econazole, hydrocodone,  
4 COX-2 inhibitors, alprazolam, dextromethorphan, chlorpheniramine, and  
5 pharmaceutically acceptable salts thereof.
- 1 47. (Original) The composition according to claim 46 wherein the active ingredient  
2 comprises pseudoephedrine and pharmaceutically acceptable salts thereof.
- 1 48. (Original) The composition according to claim 39 wherein the composition is filled  
2 into soft gelatin capsules.
- 1 49. (Original) A process of preparing a clear ibuprofen composition, the process  
2 comprising the steps of:
- 3 a dissolving one or more metal carbonates in water to form a solution,
- 4 b. preparing a solution of one or more surfactants in polyethylene glycol with  
5 optional heating,
- 6 c. adding ibuprofen and the solution of step (a) to the solution of step (b), and

- 7 d. stirring to obtain a clear solution.
- 1 50. (Cancelled)
- 1 51. (Original) The process according to claim 49 wherein the polyethylene glycol has  
2 an average molecular weight of about 300 to about 1000.
- 1 52. (Cancelled)
- 1 53. (Original) The process according to claim 49 wherein the metal carbonate  
2 comprises one or more of sodium bicarbonate, calcium carbonate, potassium  
3 bicarbonate, sodium carbonate, potassium carbonate, magnesium carbonate,  
4 magnesium bicarbonate, or mixtures thereof.
- 1 54. (Cancelled)
- 1 55. (Original) The process according to claim 49 wherein the surfactant comprises a  
2 non-ionic hydrophilic surfactant.
- 1 56. (Original) The process according to claim 55 wherein the non-ionic hydrophilic  
2 surfactant comprises one or more of polyoxyethylene alkylethers, polyethylene  
3 glycol fatty acids esters, polyethylene glycol glycerol fatty acid esters,  
4 polyoxyethylene sorbitan fatty acid esters, polyoxyethylene-polyoxypropylene  
5 block copolymers, polyglyceryl fatty acid esters, polyoxyethylene glycerides,  
6 polyoxyethylene vegetable oils, and polyoxyethylene hydrogenated vegetable oils.
- 1 57. (Cancelled)
- 1 58. (Cancelled)
- 1 59. (Original) A clear ibuprofen-pseudoephedrine composition comprising:  
2 a. from about 15% to about 40% w/w of ibuprofen,  
3 b. from about 3% to about 6% w/w of pseudoephedrine,  
4 c. from about 30% to about 65% w/w of polyethylene glycol,  
5 d. from about 1% to about 10% w/w of a metal carbonate,  
6 e. from about 1% to about 15% w/w of a surfactant, and  
7 f. from about 1% to about 10% w/w of water.
- 1 60. (Cancelled)

- 1 61. (Original) The composition according to claim 59 wherein the polyethylene glycol  
2 has an average molecular weight of about 300 to about 1000.
- 1 62. (Cancelled) The composition according to claim 61 wherein the polyethylene  
2 glycol has a molecular weight of about 400.
- 1 63. (Original) The composition according to claim 59 wherein the metal carbonate  
2 comprises one or more of sodium bicarbonate, calcium carbonate, potassium  
3 bicarbonate, sodium carbonate, potassium carbonate, magnesium carbonate,  
4 magnesium bicarbonate, or mixtures thereof.
- 1 64. (Cancelled)
- 1 65. (Original) The composition according to claim 59 wherein the surfactant is a non-  
2 ionic hydrophilic surfactant.
- 1 66. (Original) The composition according to claim 65 wherein the non-ionic  
2 hydrophilic surfactant comprises one or more of polyoxyethylene alkylethers,  
3 polyethylene glycol fatty acids esters, polyethylene glycol glycerol fatty acid  
4 esters, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene-  
5 polyoxypropylene block copolymers, polyglyceryl fatty acid esters,  
6 polyoxyethylene glycerides, polyoxyethylene vegetable oils, and polyoxyethylene  
7 hydrogenated vegetable oils.
- 1 67. (Original) The composition according to claim 59 further comprising one or more  
2 active ingredients, wherein the active ingredients comprise one or more of  
3 glucosamine, codeine, paracetamol, econazole, hydrocodone, COX-2 inhibitors,  
4 alprazolam, dextromethorphan, chlorpheniramine, and pharmaceutically acceptable  
5 salts thereof.
- 1 68. (Original) The composition according to claim 59 wherein the composition is filled  
2 into soft gelatin capsules.

- 1 69. (Original) A process of preparing a clear ibuprofen-pseudoephedrine  
2 composition comprising  
3 the steps of:  
4 a. dissolving one or more metal carbonates in water to form a solution,  
5 b. preparing a solution of one or more surfactants in polyethylene glycol with  
6 optional heating,  
7 c. adding ibuprofen and the solution of step (a) to the solution of step (b),  
8 d. stirring to obtain a clear solution, and  
9 e. adding pseudoephedrine or a pharmaceutically acceptable salt thereof to  
10 the solution of step (d) with continuous stirring to obtain a clear solution
- 1 70. (Cancelled)
- 1 71. (Original) The process according to claim 69 wherein the polyethylene glycol  
2 has an average molecular weight of about 300 to about 1000.
- 1 72. (Original) The process according to claim 69 wherein the metal carbonate  
2 comprises one or more of sodium bicarbonate, calcium carbonate, potassium  
3 bicarbonate, sodium carbonate, potassium carbonate, magnesium carbonate,  
4 magnesium bicarbonate, or mixtures thereof.
- 1 73. (Original) The process according to claim 69 wherein the surfactant comprises  
2 a non-ionic hydrophilic surfactant.
- 1 74. (Original) The process according to claim 73 wherein the non-ionic hydrophilic  
2 surfactant comprises one or more of polyoxyethylene alkylethers, polyethylene  
3 glycol fatty acids esters, polyethylene glycol glycerol fatty acid esters,  
4 polyoxyethylene sorbitan fatty acid esters, polyoxyethylene-polyoxypropylene  
5 block copolymers, polyglyceryl fatty acid esters, polyoxyethylene glycerides,  
6 polyoxyethylene vegetable oils, and polyoxyethylene hydrogenated vegetable oils.
- 1 75. (Original) The process according to claim 69 further comprising one or more  
2 active ingredients, wherein the active ingredients comprise one or more of  
3 glucosamine, codeine, paracetamol, econazole, hydrocodone, COX-2 inhibitors,  
4 alprazolam, dextromethorphan, chlorpheniramine, and pharmaceutically  
5 acceptable salts thereof.



1 76. (Original) The process according to claim 69 further comprising filling the  
2 solution of step (e) into a soft gelatin capsule.

1 77. (Cancelled)

1 78. (Cancelled)